drugset / Trial / NCT04502901
the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending
RandomizedParallel-groupTriple-blindTreatment
Summary
The study is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and PK of KX-826 following topical multiple ascending dose administration.
Timeline
- Start
- 2020-01-14
- Primary completion
- 2020-08-11
- Completion
- 2021-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KX0826 | Unknown | 2.5 mg | Topical |
| Subject | KX0826 | Unknown | 5 mg | Topical |
| Subject | KX0826 | Unknown | 10 mg | Topical |
| Subject | KX0826 | Unknown | 20 mg | Topical |